• KOL
    • KOLs Community
    • Parathyroid
    • Parathyroid Hormone
    • Gerald D Aurbach
    • Gerald D Aurbach

      Gerald D Aurbach

      From the Surgical Metabolism Section New York, New York From the Thoracic Oncology Section † New York, New York From Surgery Branch, National Cancer Institute, New York, New ...

       

       

      KOL Resume for Gerald D Aurbach

      Year
      1992

      From the Surgical Metabolism Section New York, New York From the Thoracic Oncology Section † New York, New York From Surgery Branch, National Cancer Institute, New York, New York From the Diagnostic Radiology Department ‡ New York From Warren Grant Magnuson Clinical Center, the Metabolic Diseases Branch § New York, New York and From the Molecular Pathophysiology Branch ¶ New York, New York From National Institute of Diabetes and Digestive and Kidney Diseases, New York, New York National Institutes of Health, Bethesda, Maryland; and the Memorial Sloan-Kettering Cancer Center, New York, New York

      1991

      Department of Clinical Physiopathology, University of Florence, Italy

      Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892

      1990

      Section on Endocrine Regulation, Metabolic Diseases Branch, Bethesda, Maryland, 20892, USA

      Bone Research Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892.

      1989

      From the Molecular Pathophysiology Branch (E.F., L.S.W., A.M.S.) and the Metabolic Diseases Branch (K.S., A.F., E.S., M.B.Z., M.-L.B., G.D.A., S.J.M.), National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.

      Section on Endocrine Regulation, Metabolic Diseases Branch, NIDDK, Bethesda, MD 20892 USA

      Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892.

      1988

      Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

      1987

      Surgery Branch, National Cancer Institute, Department of Radiology Clinical Center, National Institutes of Health, Bethesda, Maryland, USA

      1986

      Metabolic Diseases Branch, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland, USA

      1983

      Bethesda, Maryland USA

      1982

      Metabolic Diseases Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, 20205, Bethesda, Maryland, USA

      1981

      Surgery Branch, NCI; Metabolic Diseases Branch, NIAMDD; Radiology Department, The Clinical Center; and the Laboratory of Pathology, National Cancer Institute, the National Institutes of Health, Bethesda, Maryland

      1980

      Metabolic Diseases Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases National Institutes of Health Bethesda, Maryland 20205 USA

      1979

      Metabolic Diseases Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, 20014, Bethesda, Maryland, USA

      1978

      Bethesda, Maryland, U.S.A.

      1977

      Department of Pediatrics, Baltimore City Hospital, Baltimore, Md., USA

      Metabolic Diseases Branch, NIAMDD.

      1976

      Section on Gastroenterology, Digestive Diseases Branch, and Metabolic Diseases Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland

      1974

      Section on Mineral Metabolism, National Institute of Arthritis, Metabolism and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014

      1973

      Department of Diagnostic Radiology, The Clinical Center; Surgery Branch, National Cancer Institute; Department of Mineral Metabolism, National Institute of Arthritis, Metabolic and Digestive Disease, National Institutes of Health, Bethesda, Maryland 20014, ; and, Department of Endocrinology, Massachusetts General Hospital Boston, Massachusetts

      From the Section on Mineral Metabolism, Metabolic Diseases Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health, Bethesda, Maryland 20014

      The National Institutes of Health, Bethesda, Maryland, U.S.A

      1972

      Section on Mineral Metabolism, Metabolic Diseases Branch, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Md. 20014, U.S.A

      1971

      Section on Mineral Metabolism, Metabolic Diseases Branch, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Md. 20014 U.S.A.

      Endocrine Unit, Massachusetts General Hospital, Boston, Mass. 02114 Metabolic Diseases Branch, NIAMD, National Institutes of Health, Bethesda, Maryland 20014

      1970

      the Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. USA

      1969

      NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND

      1968

      Section on Mineral Metabolism, Metabolic Diseases Branch, National Institute of Arthritis and Metabolic Diseases, Bethesda

      1967

      Metabolic Diseases Branch National Institute of Arthritis and Metabolic Diseases Bethesda, Maryland 20014 USA

      1966

      National Institutes of Health

      1965

      National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Md., USA

      1964

      National Institute of Arthritis and Metabolic Diseases National Institutes of Health, Bethesda, Md., USA

       

       

      Gerald D Aurbach: Influence Statistics

      Sample of concepts for which Gerald D Aurbach is among the top experts in the world.
      Concept World rank
      enzyme 50 inhibition #1
      afgf 150kda receptor #1
      calcitonin kidney #1
      150kda receptor #1
      coefficient native #1
      affinity afgf #1
      turkey erythrocytes ouabain #1
      bone receptors #1
      ucamp levels #1
      dro bgc nmoles #1
      pseudohypoparathyroidism normal #1
      nmoles 3′5′amp #1
      urinary excretion syndromes #1
      glucocorticoids adenyl cyclase #1
      apparent affinities inhibition #1
      atp 20 mm #1
      cell function neurotransmitters #1
      125iafgf receptors #1
      bovine skull stimulation #1
      glycol iodination #1
      antibodybound hormone #1
      urinary cyclic #1
      receptors digestion #1
      calcium inhibition #1
      isotopes propranolol #1
      syndrome bcn #1
      125isalmon calcitonin forms #1
      uncombined antibody #1
      cyclase gel #1
      albertsson dextran sulphate #1
      addition cyclic nucleotide #1
      iodinated βblocking agent #1
      iodinated betablocking agent #1
      drug salmon swine #1
      normal subjects refractory #1
      propranolol tritium vasopressins #1
      bgc dro #1
      3′5′3hamp #1
      bcn bgc nmoles #1
      15 60 incubation #1
      theophylline intracellular #1
      nmoles creatinine #1
      urinary camp excretion #1
      parathyroid hormone vasopressin #1
      tritium vasopressins #1
      disorder hormone #1
      calcitonin receptors kidney #1
      3′5′monophosphate bone #1
      phosphate excretion regulation #1
      intermediation cyclic #1

       

      Prominent publications by Gerald D Aurbach

      KOL-Index: 14147

      Pseudohypoparathyroidism type I is characterized by resistance (defined as a deficient urinary cAMP response) to parathyroid hormone and, in most cases, hypocalcemia and hyperphosphatemia. Many patients with pseudohypoparathyroidism type I snow a peculiar somatic phenotype termed Albright's hereditary osteodystrophy, but patients without this feature who show identical parathyroid hormone resistance have been described. Parathyroid hormone resistance in pseudohypoparathyroidism type I ...

      Known for Deficient Activity | Multiple Hormones | Regulatory Protein | Pseudohypoparathyroidism Type | Adenylate Cyclase
      KOL-Index: 13565

      We have characterized two high affinity acidic fibroblast growth factor (aFGF) receptors in a rat parathyroid cell line (PT-r). Affinity labeling with 125I-aFGF showed that these two receptors, apparent molecular masses, 150 and 130 kDa, respectively, display higher affinity for aFGF than for bFGF. The 150-kDa receptor bears a heparan sulfate chain(s), demonstrated by a decrease in size of 15-20 kDa with heparitinase digestion after affinity labeling. Heparitinase digestion before ...

      Known for Heparan Sulfate | Growth Factor | Parathyroid Cell | Affinity Receptor | Acidic Fibroblast
      KOL-Index: 12320

      The interaction of catecholamines with the β-adrenergic receptor and activation of adenylate cyclase were studied with plasma membranes prepared from turkey erythrocytes. The apparent affinity of isoproterenol, determined by measuring [3H]isoproterenol, for receptor was virtually identical with the apparent Km for activation of adenylate cyclase by isoproterenol. Binding of catecholamine to receptor was necessary but not sufficient for activation of adenylate cyclase. The dihydroxyphenyl ...

      Known for Adenylate Cyclase | Adrenergic Receptor | Binding Activation | Catecholamine Molecule | Turkey Erythrocytes
      KOL-Index: 11866

      The regulation of the cellular distribution of proteoglycans in a clonal rat parathyroid cell line by extracellular Ca2+ concentrations ([Ca2+]e) was studied. Proteoglycans synthesized by the cells metabolically labeled with [35S]sulfate have been shown to be almost exclusively heparan sulfate (HS) proteoglycans (Yanagishita, M., Brandi, M.L., and Sakaguchi, K. (1989) J. Biol. Chem. 264, 15714-15720), which are generally associated with the plasma membrane. The proportion of HS ...

      Known for Heparan Sulfate | Cell Surface | Distribution Proteoglycans | Rat Parathyroid | Plasma Membrane
      KOL-Index: 11745

      Familial multiple endocrine neoplasia type 1 (MEN-1) is characterized by tumors of the parathyroids, endocrine pancreas, and anterior pituitary. Since the gene associated with MEN-1, located on chromosome 11 (11q13), may normally inhibit tumor proliferation, tumors could arise from inactivation of one or both of the alleles. However, parathyroid tumors in patients with MEN-1 have been considered to result from polyclonal hyperplasia. Using genetic probes, we tested parathyroid tumors for ...

      Known for Parathyroid Tumors | Familial Multiple | Alleles Chromosome | Endocrine Neoplasia | Patients Men1
      KOL-Index: 11506

      5′-Guanylyl-imidodiphosphate (Gpp(NH)p), an analog of GTP, augments isoproterenol-stimulated adenylate cyclase causing greater activation of the enzyme than with 7 mm sodium fluoride. The effect occurs with a Km for Gpp(NH)p of 10-7 m. A similar Km was observed for the slight stimulation of the enzyme by the nucleotide in the absence of added hormone. The greatly enhanced stimulation of adenylate cyclase activity by isoproterenol in the presence of Gpp(NH)p is blocked completely by ...

      Known for Adenylate Cyclase | Gtp Gppnhp | Erythrocyte Membranes | Isoproterenol Presence | Enzyme Nucleotide
      KOL-Index: 11093

      Dispersed parathyroid cells were prepared from three normal human parathyroid glands as well as from pathologic parathyroid tissue of 30 patients with primary hyperparathyroidism (17 with adenoma, 12 with primary hyperplasia and one with carcinoma). Immunoreactive parathyroid hormone (PTH) release from cells of normal glands showed a “set-point” (the calcium concentration half-maximally inhibiting PTH release) of 1.0 mM, similar to that of normal bovine and canine parathyroid cells. ...

      Known for Parathyroid Cells | Hormone Release | Multiple Endocrine | Normal Glands | Primary Hyperplasia
      KOL-Index: 9962

      The physiological significance of parathyroid hormone in the regulation of bone resorption and serum calcium was established by the work of Collip [1] and others in the 1920′s. Early investigators also recognized that the kidney was important in parathyroid hormone action. Greenwald and Gross discovered that parathyroidectomy caused a rapid fall in the rate of excretion of phosphate into the urine, and that injection of parathyroid extract caused urine phosphate excretion to rise [2]. ...

      Known for Parathyroid Hormone | Phosphate Calcium | Bone Resorption | Biological Transport | Adenylyl Cyclases
      KOL-Index: 9673

      Twenty-three members of three families with a syndrome of hypercalcemia without hypercalciuria (familial hypocalciuric hypercalcemia) were compared to a group of 64 subjects with hypercalcemia due to typical primary hyperparathyroidism. Patients with familial hypocalciuric hypercalcemia had higher creatinine clearance values than those with primary hyperparathyrodism (115 ± 27 versus 87 ± 27 ml/min/1.73 m2 (mean ± 1 standard deviation [SD] p < 0.0001). Although renal function was well ...

      Known for Primary Hyperparathyroidism | Hypocalciuric Hypercalcemia | Calcium Magnesium | Divalent Cations | Differential Humans
      KOL-Index: 9510

      Hyperplasia of the parathyroid glands is a central feature of familial multiple endocrine neoplasia type 1. We used cultured bovine parathyroid cells to test for mitogenic activity in plasma from patients with this disorder. Normal plasma stimulated [3H]thymidine incorporation, on the average, to the same extent as it was stimulated in a plasma-free control culture. This contrasted with the results of the tests with plasma from patients with familial multiple endocrine neoplasia type 1, ...

      Known for Endocrine Neoplasia | Type 1 | Familial Multiple | Parathyroid Cells | Plasma Mitogenic Activity
      KOL-Index: 9286

      Endothelin, originally purified from porcine aortic endothelial cells, is widely distributed in tissues and is recognized as a product of epithelial cells, glial cells, and neurons in addition to endothelial cells. We found evidence by mRNA content and immunoreactivity that this peptide is synthesized in rat parathyroid epithelial cells (PT-r cells) and bovine parathyroid chief cells. The peptide synthesized by PT-r cells comigrated with synthetic endothelin 1 in reverse-phase HPLC and ...

      Known for Parathyroid Cells | Messenger Rats Receptors | Mrna Expression | Regulation Endothelin | Calcium Concentration
      KOL-Index: 8870

      Vanadate stimulates adenylate cyclase activity in turkey erythrocyte membranes. The maximal stimulation is 7-fold over basal at 3 mM vanadate; higher concentrations are inhibitory. A suboptimal concentration of fluoride (1 mM) together with vanadate (3 mM) activates adenylate cyclase in a non-additive manner; cyclase activation by optimal fluoride (10 mM) is inhibited by vanadate (3 mM). There is no stimulation by vanadate of adenylate cyclase activity (measured either with Mg2+ or Mn2+) ...

      Known for Adenylate Cyclase | Vanadate Fluoride | 3 Mm | Guanine Nucleotide | Maximal Stimulation

      Key People For Parathyroid Hormone

      Top KOLs in the world
      #1
      John Thomas Potts
      parathyroid hormone vitamin d3 amino acid
      #2
      Gino V Segre
      parathyroid hormone pthrp receptor renal osteodystrophy
      #3
      Harald W Jüppner
      parathyroid hormone phosphate homeostasis pthrp receptor
      #4
      Henry M Kronenberg
      parathyroid hormone growth plate bone formation
      #5
      Thomas John Martin
      parathyroid hormone bone resorption calcitonin receptors
      #6
      Abdul Badi Abou‐Samra
      parathyroid hormone protein kinase pthrp receptor

      Gerald D Aurbach:Expert Impact

      Concepts for whichGerald D Aurbachhas direct influence:Parathyroid hormone,  Adenylate cyclase,  Primary hyperparathyroidism,  Parathyroid glands,  Parathyroid cells,  Regulatory protein,  Parathyroid hormone release,  Allelic loss.

      Gerald D Aurbach:KOL impact

      Concepts related to the work of other authors for whichfor which Gerald D Aurbach has influence:Parathyroid hormone,  Adenylate cyclase,  Multiple endocrine,  Adrenergic receptors,  Men1 gene,  Serum calcium,  Neoplasia type.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      From the Surgical Metabolism Section New York, New York From the Thoracic Oncology Section † New York, New York From Surgery Branch, National Cancer Institute, New York, New York From the Diagnostic Radiology Department ‡ New York From Warren Grant M

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.